Please ensure Javascript is enabled for purposes of website accessibility

Why Illumina Stock Gained 12% in February

By Demitri Kalogeropoulos – Updated Apr 11, 2019 at 8:16AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were happy to hear that management is expecting a 21st straight year of sales growth in 2019.

What happened

Shares of biotech giant Illumina (ILMN -0.11%) outpaced the market last month, gaining 12% compared to a 3% increase in the S&P 500, according to data provided by S&P Global Market Intelligence.

The move added to solid returns for shareholders lately, with the stock having outperformed the broader market over the past year.

A male and a female scientist looking at a petri dish under a microscope

Image source: Getty Images.

So what

February's rally came as investors digested generally strong fourth-quarter results that were released in the final days of January. Yes, sales growth slowed when compared to the third quarter. However, Illumina still expanded revenue at a double-digit pace, and growth would have been faster if not for the distortion caused by recent tariffs.

Check out the latest earnings call transcript for Illumina.

Now what

CEO Francis deSouza and his executive team said in a conference call with analysts that management expects revenue to rise by between 13% and 14% in 2019. That result would be a slowdown from the past year's 21% spike. Yet it would also mark the gene sequencing giant's 21st consecutive year of growth. That impressive streak is a testament to Illumina's strong market position across several attractive niches in the healthcare treatment industry. As long as the company can defend that valuable posture, the stock should continue to outperform.

Demitrios Kalogeropoulos has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Illumina. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.